Jimenez-Labaig, P, Pacheco-Barcia, V, Cebria, A, Galvez, F, Obispo, B, Paez, D, Quilez, A, Quintanar, T, Ramchandani, A, Remon, J, Rogado, J, Sanchez, DA, Sanchez-Canovas, M, Sanz-Garcia, E, Sesma, A, Tarazona, N, Cotes, A, Gonzalez, E, Bosch-Barrera, J, Fernandez, A, Felip, E, Vera, R, Rodriguez-Lescure, A, Elez, E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021; 6(4)DOI:10.1016/j.esmoop.2021.100215. PMID:34325108. IF:6.883(Q1/3D).

Wilson, BE, Desnoyers, A, Nadler, MB, Tibau, A, Amir, E. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. Cancer Medicine. 2021; 10(16)DOI:10.1002/cam4.4029. PMID:34323019. IF:4.711(Q2/5D).

Gil-Gil, MJ, Bellet, M, Bergamino, M, Morales, S, Barnadas, A, Manso, L, Saura, C, Fernandez-Ortega, A, Garcia-Martinez, E, Martinez-Janez, N, Mele, M, Villagrasa, P, Celiz, P, Martin, XP, Ciruelos, E, Pernas, S. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Frontiers in Oncology. 2021; 11DOI:10.3389/fonc.2021.645026. PMID:34307126. IF:5.738(Q2/4D).

Provencio, M, Gallego, JMM, Calles, A, Antonanzas, M, Pangua, C, Rubio, XM, Nadal, E, Castro, RL, Lopez-Martin, A, Del Barco, E, Domine, M, Franco, F, Diz, P, Sandoval, C, Girona, ES, Sullivan, I, Sala, MA, Ledo, GG, Cucurull, M, Mosquera, J, Martinez, M, Chara, LE, Arriola, E, Herrera, BE, Jarabo, JR, Alvarez, RA, Baena, J, Cao, MG. Lung cancer patients with COVID-19 in Spain: GRAVID study. LUNG CANCER. 2021; 157DOI:10.1016/j.lungcan.2021.05.014. PMID:34016490. IF:6.081(Q1/3D).

Mezquita, L, Preeshagul, I, Auclin, E, Saravia, D, Hendriks, L, Rizvi, H, Park, W, Nadal, E, Martin-Romano, P, Ruffinelli, JC, Ponce, S, Audigier-Valette, C, Carnio, S, Blanc-Durand, F, Bironzo, P, Tabbo, F, Reale, ML, Novello, S, Hellmann, MD, Sawan, P, Girshman, J, Plodkowski, AJ, Zalcman, G, Majem, M, Charrier, M, Naigeon, M, Rossoni, C, Mariniello, A, Paz-Ares, L, Dingemans, AM, Planchard, D, Cozic, N, Cassard, L, Lopes, G, Chaput, N, Arbour, K, Besse, B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. EUROPEAN JOURNAL OF CANCER. 2021; 151DOI:10.1016/j.ejca.2021.03.011. PMID:34022698. IF:10.002(Q1/2D).

Alvarez-Mancenido, F, Jimenez-Fonseca, P, Carmona-Bayonas, A, Arrazubi, V, Hernandez, R, Cano, JM, Custodio, A, Pijaume, CP, Aguado, G, Lago, NM, Canovas, MS, Lavin, DC, Visa, L, Martinez-Torron, A, Arias-Martinez, A, Lopez, F, Limon, ML, Tocino, RV, Montes, AF, Alsina, M, Pimentel, P, Reguera, P, Carnicero, AM, Ramchandani, A, Granja, M, Azkarate, A, Richard, MM, Serra, O, Perez, CH, Hurtado, A, Gil-Negrete, A, Sauri, T, del Burgo, PM, Gallego, J. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer. 2021; 24(4)DOI:10.1007/s10120-021-01169-6. PMID:33651195. IF:7.701(Q1/2D).

Laza-Briviesca, R, Cruz-Bermudez, A, Nadal, E, Insa, A, Garcia-Campelo, MD, Huidobro, G, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Casarrubios, M, Sierra-Rodero, B, Tarin, C, Garcia-Grande, A, Haymaker, C, Wistuba, II, Romero, A, Franco, F, Provencio, M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine. 2021; 11(7)DOI:10.1002/ctm2.491. PMID:34323406. IF:8.554(Q1/2D).

Atenza, CZ, Anguera, G, Melia, MR, De Lamo, LA, Sullivan, I, Joaquin, AB, Lopez, JS, Ortiz, MA, Mulet, M, Vidal, S, Majem, M. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2022; 71(8)DOI:10.1007/s00262-021-03107-y. PMID:34984538. IF:5.800(Q1/3D).